peptides for erectile FAQ

Not automatically. Switch to PT-141 only after confirming the failure mechanism. If sildenafil fails because nitric oxide signaling is impaired (common in diabetics, patients with severe endothelial dysfunction, or those on nitrates), PT-141's melanocortin pathway bypasses that bottleneck and has a high probability of working. If sildenafil fails because the patient has low baseline arousal or psychological barriers, PT-141 may also fail because it still requires some level of psychological receptivity to sexual stimuli. It initiates arousal centrally but doesn't override complete lack of desire. Request a serum testosterone level and assess for hypogonadism before escalating to PT-141.

Use hexarelin or a GH secretagogue protocol. Hexarelin increases eNOS expression and endothelial cell proliferation, addressing the root vascular pathology rather than compensating for it acutely. A 12-week hexarelin protocol (100mcg daily subcutaneous) increases nitric oxide production capacity measurably and improves erectile function scores by 6+ points even after discontinuation, suggesting durable vascular remodeling rather than temporary symptom relief.

VIP produces the fastest onset (5–15 minutes when injected intracavernously) but isn't practical for most protocols due to injection site requirements. PT-141 has the fastest systemically administered onset at 45–90 minutes via subcutaneous injection, making it the most practical choice for research requiring same-day response measurement. Hexarelin and GH secretagogues require weeks to months and aren't suitable for acute-response protocols.

Start with PT-141 if arousal is the issue, or BPC-157 if vascular damage is suspected. Sildenafil non-response often indicates either absent arousal signalling (psychogenic ED, SSRI-induced blunted libido) or severe endothelial dysfunction where nitric oxide synthesis is too impaired for PDE5 inhibition to maintain anything. PT-141 generates arousal centrally, which initiates the entire erectile cascade regardless of peripheral vascular status. If doppler ultrasound shows reduced penile arterial flow or you have diabetes, hypertension, or smoking history, BPC-157's endothelial repair mechanism addresses the root vascular deficiency that sildenafil can't fix.

Discard them. Peptides are proteins. Even brief temperature excursions above 8°C cause conformational changes that eliminate biological activity. Lyophilised (freeze-dried) peptides tolerate room temperature storage before reconstitution, but once mixed with bacteriostatic water, the peptide is in solution and vulnerable to denaturation. A vial left out overnight is biologically inactive regardless of appearance. Refrigerate reconstituted peptides immediately at 2–8°C and use within 28 days. Longer storage periods risk bacterial growth even with bacteriostatic water.

Research protocols routinely combine peptides targeting different pathways. Pairing PT-141 (central arousal) with BPC-157 (vascular repair) addresses both immediate arousal deficits and long-term structural damage. The mechanisms don't overlap or interfere. Adding GHRP-6 (hormonal support) creates a three-mechanism approach covering neurological, vascular, and endocrine contributors to ED. The constraint is injection volume and timing: PT-141 is dosed acutely before activity, while BPC-157 and GHRP-6 require daily administration on an empty stomach for cumulative effect. Consult a physician supervising peptide research protocols before combining compounds.

Discard the solution and reconstitute a fresh aliquot. Peptides with cyclic structures (bremelanotide) or methionine residues (kisspeptin, VIP) undergo irreversible aggregation and oxidation when exposed to temperatures above 8°C for extended periods. The pharmacological consequence is not partial potency loss. It is complete structural denaturation. Visual clarity is not a reliable indicator; aggregated peptides often remain optically clear while forming high-molecular-weight complexes that cannot bind target receptors. For any research protocol requiring dose-response accuracy, temperature excursions above the 2–8°C storage range invalidate the batch.

Kisspeptin analogues become the mechanistically appropriate investigational compound. PDE5 inhibitors and melanocortin agonists improve erectile signaling but do not address upstream hormonal deficiency. Men with serum testosterone below 8 nmol/L (231 ng/dL) exhibit suppressed nitric oxide synthase expression, reduced cavernosal smooth muscle content, and impaired response to sexual stimuli. Sildenafil amplifies a signal that hypogonadism has already diminished. Kisspeptin-10 restores GnRH pulsatility, driving endogenous LH and testosterone production. The 2023 Imperial College trial demonstrated LH increases of 4.1-fold from baseline and testosterone elevations of 6.5 nmol/L within 24 hours. Physiological restoration rather than exogenous supplementation.

Discard immediately. Particulate formation indicates protein aggregation, precipitation, or bacterial contamination, any of which renders the solution unsuitable for research use. Even if the majority of the solution remains clear, the presence of visible particles signals that peptide degradation has begun and the amino-acid sequence is no longer intact. Bacteriostatic water extends reconstituted peptide stability to 28 days under ideal conditions (2–8°C, amber vial, no freeze-thaw cycles), but this assumes sterile reconstitution technique and zero contamination. Particulate matter is a hard stop.

VIP plus phentolamine provides a mechanistic probe. If intracavernosal administration of VIP (which bypasses NO pathways and activates cAMP-mediated smooth muscle relaxation) combined with phentolamine (which removes alpha-adrenergic vasoconstriction) produces a rigid erectile response, the dysfunction is likely vascular or neurogenic with intact smooth muscle. If the combination fails, the issue is cavernosal fibrosis, Peyronie's disease, or venous leak. Structural pathologies that neither NO-dependent nor cAMP-dependent pharmacological interventions can overcome. This diagnostic application is particularly valuable in diabetic and post-prostatectomy populations where multiple dysfunction mechanisms often coexist.

Reduce the dose to 0.75mg on subsequent administrations and consider pretreatment with an antiemetic like ondansetron 30 minutes before peptide injection. Nausea severity correlates directly with dose magnitude. The 1.75mg dose used in pivotal trials produced nausea in 40% of participants, while 0.75mg reduced incidence to roughly 15%. Slower injection speed (10–15 seconds rather than 5 seconds) also lowers peak nausea by reducing the rate of plasma concentration rise.

Discard the vial. Peptides degrade exponentially at room temperature. Even 8–12 hours at 20–25°C causes measurable loss of potency that cannot be recovered by returning the solution to refrigeration. The degraded peptide won't harm you, but it will deliver unpredictable results ranging from reduced efficacy to complete loss of effect. Reconstitute a fresh vial rather than risk wasted administration.

PT-141 addresses central arousal deficits, not purely mechanical erectile dysfunction from vascular insufficiency. If your ED stems from severe arterial blockage, venous leak, or significant endothelial dysfunction, melanocortin receptor activation won't overcome the structural vascular limitation. Consider whether your ED is accompanied by low libido or reduced spontaneous erections. If libido is normal but mechanical function is impaired, PDE5 inhibitors or combination therapy may be more appropriate. Peptide therapy works best for men whose erectile difficulties are tied to reduced desire or neurological signaling rather than blood flow alone.

Your erectile dysfunction is not testosterone-dependent. The HPG axis responded correctly, but peripheral vascular or smooth muscle function remains impaired. This pattern is common in men with diabetes or atherosclerotic disease where nitric oxide signaling is disrupted independent of hormone levels. Combine Kisspeptin-10 with a PDE5 inhibitor to address both hormonal and vascular components, or discontinue Kisspeptin-10 and rely on PDE5 inhibition alone if testosterone normalization provides no subjective benefit.

Increase the dose to 2.0mg subcutaneous for the second trial. Phase 3 data showed that 18% of non-responders at 1.75mg achieved response at 2.0mg. If two doses at 2.0mg produce no measurable effect, PT-141 is unlikely to work for you because your dysfunction pattern is probably vascular rather than central. Switch to Kisspeptin-10 evaluation if low testosterone is suspected, or trial PDE5 inhibitors if vascular insufficiency is the likely cause.

Reduce the dose to 0.25mg and pre-medicate with 25mg meclizine (Dramamine) 30 minutes before injection. This protocol reduced nausea from 60% to 22% in a 2021 tolerability study. Titrate the Melanotan II dose upward by 0.25mg every third administration until you reach minimal effective dose. If nausea persists at 0.5mg despite antiemetic pre-treatment, discontinue Melanotan II and switch to PT-141, which produces nausea in only 40% of users and at lower severity.

Nausea occurs in approximately 30–40% of men during initial PT-141 or melanotan II administration due to melanocortin receptor activation in the brainstem area postrema, which regulates nausea and emesis. Dose reduction (starting at 0.5mg for melanotan II or 1mg for PT-141) and slow titration over 2–3 administrations typically resolves symptoms as central melanocortin receptors downregulate. Flushing results from peripheral vasodilation and usually resolves within 60–90 minutes. Pretreatment with an H2-receptor antagonist (famotidine 20mg) may reduce flushing intensity without impairing erectile response.

Kisspeptin-10 stimulates endogenous LH and FSH release without suppressing the hypothalamic-pituitary axis, meaning it does not cause testicular atrophy or spermatogenic shutdown the way exogenous testosterone does. This makes kisspeptin-10 the only hormonal intervention that can restore testosterone levels while preserving or even enhancing fertility. Exogenous testosterone replacement would suppress FSH and halt spermatogenesis within 8–12 weeks, making it unsuitable for men planning conception.

Combination protocols may be appropriate. Kisspeptin-10 to restore testosterone production and PT-141 to address central arousal deficits. The two peptides act on distinct pathways and do not compete or interfere mechanistically. Clinical trials have not formally evaluated this combination, but the pharmacological rationale is sound: normalize hormonal support first (kisspeptin-10 administered daily for 2–4 weeks to restore baseline testosterone), then address residual arousal or performance anxiety with PT-141 as needed before sexual activity.

Consider PT-141 if the patient has normal nocturnal erections (indicating intact vascular capacity) but impaired arousal or performance anxiety during partnered activity. PT-141 targets central arousal pathways that sildenafil does not address. If the patient has diabetes, hypertension, or documented endothelial dysfunction, VIP or melanotan II may address peripheral vascular failure points beyond nitric oxide pathways. Kisspeptin-10 should be evaluated only if serum testosterone is below 350 ng/dL and the patient shows low LH levels, indicating hypothalamic suppression rather than primary testicular failure.